In a pioneering clinical trial, researchers have used CRISPR base editing to deactivate the PCSK9 gene in the liver, resulting in significant and sustained reductions in LDL cholesterol levels. This one-time treatment could revolutionize cardiovascular care by providing a durable solution for patients with inherited high cholesterol. For more content like this, please visit: https://t.co/IMkI8zsszz #CRISPR# #GeneEditing# #Cholesterol# #HeartHealth# #MedicalInnovation#